(PharmaNewsWire.Com, May 05, 2017 ) According to Publisher, the Global Coronary Artery Bypass Graft (CABG) market is accounted for $76.4 million in 2016 and is expected to reach $119.27 million by 2022 growing at a CAGR of 7.7% from 2016 to 2022. Factors such as widespread occurrence of coronary heart diseases, favorable reimbursement policies and technologically advanced products are driving the market growth. However, expensive healthcare budgets and payment structure are barriers for the market growth. In addition, the major challenge to the market is availability of minimally invasive alternative options such as percutaneous coronary interventions.
The off-pump CABG device is projected to be the fastest growing segment during the forecast period as it is a relatively new technology such as emergence of Totally Endoscopic Robotically Assisted Coronary Artery Bypass (TECAB). The endoscopic vein harvesting technique segment is anticipated to grow fast during the forecast period owing to reduce long incisions and reducing the risk of infection and complications. However, the conventional vessel harvesting technique segment will dominate the market due to its higher utilization in coronary artery bypass graft procedures. The Triple CABG Surgeries segment is expected to dominate the Coronary Surgical Procedure market owing to the rising prevalence of coronary heart disease and strokes. North America is the leading Market for Coronary Artery Bypass Graft (CABG) followed by Europe owing to large patient population pool, changing lifestyle and increasing minimally invasive coronary artery bypass grafts surgeries. Asia Pacific region is expected to grow at fastest rate because of increasing medical tourism industry. Some of the key players in global Coronary Artery Bypass Graft (CABG) market are Abbott Laboratories, Boston Scientific, Cardiac Assist, Edwards Lifesciences, Genesee Biomedical Inc, Hancock Jaffe Laboratories, Inc, HeartWare Inc., KARL STORZ GmbH & Co. KG,MAQUET Holding B.V. & Co.KG ,Medtronic, Novadaq Technologies Inc, St. Jude Medical, Teleflex Medical, Terumo Cardiovascular Systems Corporation and Vitalitec International, Inc. Products Covered: -On-Pump Coronary Artery Bypass Devices -Off-Pump Coronary Artery Bypass Devices -Anastomosis Assist Devices -Endoscopic Vessel Harvesting Devices -Trans Myocardial Revascularization Devices Types Covered: -Internal Thoracic Artery Grafts -Saphenous Vein Grafts -Other Grafts -Gastroepiploic Artery -Radial Artery Surgical Procedures Covered: -Single CABG Surgeries -Double CABG Surgeries -Triple CABG Surgeries -Quadrupole CABG surgeries Techniques Covered: -Open Vessel Harvesting (OVH)/Conventional Vessel Harvesting -Endoscopic Vessel Harvesting
End Users Covered: -Cardiology Clinics -Hospitals -Research Institutes -Other End Users Regions Covered: -North America -US -Canada -Mexico -Europe -Germany -France -Italy -UK -Spain -Rest of Europe -Asia Pacific -Japan -China -India -Australia -New Zealand -Rest of Asia Pacific -Rest of the World -Middle East -Brazil -Argentina -South Africa -Egypt
Company Profiling 12.1 Abbott Laboratories 12.2 Boston Scientific 12.3 Cardiac Assist 12.4 Edwards Lifesciences 12.5 Genesee Biomedical Inc 12.6 Hancock Jaffe Laboratories, Inc 12.7 HeartWare Inc. 12.8 KARL STORZ GmbH & Co. KG 12.9 MAQUET Holding B.V. & Co.KG 12.10 Medtronic 12.11 Novadaq Technologies Inc 12.12 St. Jude Medical 12.13 Teleflex Medical 12.14 Terumo Cardiovascular Systems Corporation 12.15 Vitalitec International, Inc
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
